High-dose Inhalations of Nitric Oxide in the Treatment of Pneumonia
Key facts
- Who runs it
- Tomsk National Research Medical Center of the Russian Academy of Sciences
- Where
- Russia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 200 people, planned
- Started
- 15 Jan 2024
- Expected to end
- 15 Jan 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 200 ppm Nitric Oxide
- Sham treatment
- Record updated
- 30 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- An established diagnosis of Nosocomial Pneumonia (NP) after cardiac surgery under cardiopulmonary bypass (CPB) or hospitalization for Community-acquired pneumonia (CAP)
- Spontaneous breathing
- Age > 18 years
- Signed informed consent
- Negative result of immunochromatographic Severe acute respiratory syndrome-related coronavirus 2 rapid antigen test on the day of diagnosis of pneumonia; Diagnostic criteria for NP The diagnosis of NP is considered established when the number of points on the; Clinical Pulmonary Infection Score (CPIS) is greater than 6:; Diagnostic criteria for CAP:; Radiologically confirmed focal pulmonary opacity and at least 2 clinical symptoms and signs of the following:
- acute fever at the onset of the disease (t° > 38.0°C)
- cough with sputum
- physical signs (crepitus/fine rales, bronchial breathing, shortening of percussion sound)
- leukocytosis > 10x109/l and/or left shift (> 10%)
Who cannot take part
- Patient's participation in another clinical trial at the time of screening or within the previous 3 months
- Concomitant pulmonary disease with the need for respiratory support before the development of pneumonia
- Diagnosed infectious process of another localization (surgical site infection (SSI), acute and chronic urinary tract infection (active), catheter-related bloodstream infection, peritonitis, infective endocarditis etc.)
- History of malignancy or other irreversible diseases/conditions with a life expectancy of less than 1 year
- Presence of HIV infection
- Mechanical ventilation
- Presence of tracheostomy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, prospective randomized controlled trial. At least 2 but no more than 5 centers are expected to participate in the study.
Read full original descriptionShow less
The primary objective is to test the hypothesis that the addition of high-dose inhaled nitric oxide therapy to standard treatment has a positive effect on the clinical course of pneumonia and the structure and function of cardiopulmonary system.
Number of participants: 200, including the subproject NO-PNEUMONIA-CAP - 100 CAP participants, the subproject NO-PNEUMONIA-NP - 100 NP participants.
Number of groups: 4 Inhalation of iNO at a dose of 200 ppm for 30 minutes under the control of methemoglobin level (no more than 5%) three times a day if the patient is allocated to the main group. The general course of iNO therapy will last until the pneumonia resolves, but no more than 7 days. Recording of vital signs and safety assessment will be carried out immediately before the initiation of NO therapy and every 15 minutes after its start (pulse, blood pressure, respiratory rate, SpO2, temperature, MetHb level).
The 4 groups in the trial
- Main group with nosocomial pneumoniaTreatment being tested
Standard antibacterial therapy + Nitric Oxide 200 ppm 3 times a day for 30 minutes under the control of methemoglobin level (no more than 5%). The general course of Nitric Oxide therapy will last until the pneumonia resolves, but no more than 7 days.
Treatment: 200 ppm Nitric Oxide
- Control group with nosocomial pneumoniaExisting treatment, for comparison
Standard antibacterial therapy + medical air without Nitric Oxide 3 times a day for 30 minutes until the pneumonia resolves, but no more than 7 days.
Treatment: Sham treatment
- Main group with community acquired pneumoniaTreatment being tested
Standard antibacterial therapy + Nitric Oxide 200 ppm 3 times a day for 30 minutes under the control of methemoglobin level (no more than 5%). The general course of Nitric Oxide therapy will last until the pneumonia resolves, but no more than 7 days.
Treatment: 200 ppm Nitric Oxide
- Control group with community acquired pneumoniaExisting treatment, for comparison
Standard antibacterial therapy + medical air without Nitric Oxide 3 times a day for 30 minutes until the pneumonia resolves, but no more than 7 days.
Treatment: Sham treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effectiveness of Adding Multiple Intermittent High-dose Inhalations of Nitric Oxide to Standard Antibacterial Therapy in the Treatment of Pneumonia
- Record updated
- 30 July 2026